Killing time for cancer cells
- 20 June 2005
- journal article
- opinion
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 5 (7) , 573-580
- https://doi.org/10.1038/nrc1651
Abstract
As the signalling pathways that control cellular proliferation and death are unravelled, a range of targets have emerged as candidates for molecular cancer therapy. For their survival, cancer cells depend on a few highly activated signalling pathways; inhibition of these pathways has a strong apoptotic effect and can lead to tumour regression. But drugs that exploit this weakness, such as imatinib, have not cured patients: withdrawal of the drug leads to disease recurrence, and sustained treatment leads to the emergence of drug-resistant clones. Can cancer be cured, or will it have to be controlled as a chronic disease?Keywords
This publication has 62 references indexed in Scilit:
- The role of apoptosis in cancer development and treatment responseNature Reviews Cancer, 2005
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal Of Cancer, 2004
- PI3K/Akt and apoptosis: size mattersOncogene, 2003
- Apoptosis and melanoma chemoresistanceOncogene, 2003
- The case for early detectionNature Reviews Cancer, 2003
- Mutations in the ABL kinase domain pre-exist the onset of imatinib treatmentSeminars in Hematology, 2003
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences, 2003